SEAPORT THERAPEUTICS INC (SPTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$24.86+2.35%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SPTX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue enrollment and data generation in Phase 2b BUOY-1 trial and Phase 1 driving simulation trial for GlyphAllo targeting major depressive disorder.
Newly stated in 2026-Q2. Management reports enrollment on track in the Phase 2b BUOY-1 trial for major depressive disorder with topline data expected in first half of 2027. No revenue reported; net loss was $62.6 million in 2026-Q2. The clinical development is progressing as planned, consistent with management's stated timeline.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Not enough signal yet.
Not enough signal yet.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
Not enough signal yet.
Not investment advice. As of 2026-09-04.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Enrollment in Phase 2b BUOY-1 trial of GlyphAllo in major depressive disorder is on track with topline data expected in 1H 2027.”
Initiate Phase 2a proof-of-pharmacology trial in 2H 2026 and Phase 2b trial in 1H 2027 for GlyphAgo targeting generalized anxiety disorder.
Newly stated in 2026-Q2. Management disclosed plans to initiate Phase 2a and Phase 2b trials for GlyphAgo in generalized anxiety disorder in the second half of 2026 and first half of 2027 respectively. The company reported a net loss of $62.6 million in 2026-Q2, reflecting ongoing clinical development expenses. The development timeline is on track with management's statements.
“Company plans to initiate Phase 2a proof-of-pharmacology trial in 2H 2026 and Phase 2b trial in 1H 2027 for GlyphAgo in GAD.”
Advance preclinical and discovery programs for Glyph2BLSD, a non-hallucinogenic neuroplastogen, completing first-in-human-enabling studies by year-end 2027.
Newly stated in 2026-Q2. Management reports that Glyph2BLSD preclinical program is on track to complete first-in-human-enabling studies by end of 2027. The company’s net loss of $62.6 million in 2026-Q2 reflects ongoing R&D investment. The program is progressing consistent with management’s stated timeline.
“Glyph2BLSD is on track to complete first-in-human-enabling studies by the end of 2027.”
Use proceeds from upsized IPO and existing cash to support operating plans and clinical development through 2029.
Newly stated in 2026-Q2. Management completed an upsized IPO raising $260 million and reported cash, cash equivalents, and investments of $427.3 million as of June 30, 2026. This strong cash position is expected to fund operations into 2029, supporting ongoing clinical development. The financial position aligns with management’s stated capital allocation priorities.
“Upsized IPO raised $260 million; cash and investments totaled $427.3 million as of June 30, 2026, expected to fund operations into 2029.”